as 07-26-2024 4:00pm EST
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Upcoming Earnings Alert:
Get ready for potential market movements as CVRx Inc. CVRX prepares to release earnings report on 29 Jul 2024.
Founded: | 2000 | Country: | United States |
Employees: | N/A | City: | MINNEAPOLIS |
Market Cap: | 205.8M | IPO Year: | 2021 |
Target Price: | $13.80 | AVG Volume (30 days): | 386.5K |
Analyst Decision: | Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.47 | EPS Growth: | N/A |
52 Week Low/High: | $6.40 - $33.14 | Next Earning Date: | 07-29-2024 |
Revenue: | $42,086,000 | Revenue Growth: | 59.59% |
Revenue Growth (this year): | 31.87% | Revenue Growth (next year): | 33.29% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
VERRASTRO PAUL | CVRX | CHIEF MKTG & STRAT OFFICER | Feb 20 '24 | Sell | $21.91 | 2,545 | $55,748.23 | 2,455 | SEC Form 4 |
JOHNSON & JOHNSON | CVRX | 10% Owner | Feb 16 '24 | Sell | $25.81 | 3,725 | $96,142.25 | 4,099,575 | SEC Form 4 |
CVRX Breaking Stock News: Dive into CVRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
GlobeNewswire
11 days ago
Zacks
14 days ago
GlobeNewswire
a month ago
Zacks
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
3 months ago
The information presented on this page, "CVRX CVRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.